These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 10505300)

  • 41. Efficacy and safety of cerivastatin 0.8 mg in patients with hypercholesterolaemia: the pivotal placebo-controlled clinical trial. Cerivastatin Study Group.
    Insull W; Isaacsohn J; Kwiterovich P; Ra P; Brazg R; Dujovne C; Shan M; Shugrue-Crowley E; Ripa S; Tota R
    J Int Med Res; 2000; 28(2):47-68. PubMed ID: 10898118
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Inhibition of HMG-CoA reductase with cerivastatin lowers dense low density lipoproteins in patients with elevated fasting glucose, impaired glucose tolerance and type 2 diabetes mellitus.
    Scharnagl H; Winkler K; Mantz S; Baumstark MW; Wieland H; März W
    Exp Clin Endocrinol Diabetes; 2004 May; 112(5):269-77. PubMed ID: 15146374
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The effect of food on the absorption and pharmacokinetics of rivaroxaban.
    Stampfuss J; Kubitza D; Becka M; Mueck W
    Int J Clin Pharmacol Ther; 2013 Jul; 51(7):549-61. PubMed ID: 23458226
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Rhabdomyolisis associated with cerivastatin and cyclosporine combination therapy].
    Nicolás De Prado I; Miras López M; Morán Sánchez S; Mercader Martínez J
    Med Clin (Barc); 2002 May; 118(18):716-7. PubMed ID: 12042140
    [No Abstract]   [Full Text] [Related]  

  • 45. Evaluation of crizotinib absolute bioavailability, the bioequivalence of three oral formulations, and the effect of food on crizotinib pharmacokinetics in healthy subjects.
    Xu H; O'Gorman M; Boutros T; Brega N; Kantaridis C; Tan W; Bello A
    J Clin Pharmacol; 2015 Jan; 55(1):104-13. PubMed ID: 24990113
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Dual hepatic metabolism of cerivastatin--clarifications.
    Guyton JR; Dujovne CA; Illingworth DR
    Am J Cardiol; 1999 Aug; 84(4):497. PubMed ID: 10468102
    [No Abstract]   [Full Text] [Related]  

  • 47. Cerivastatin modulates plasma paraoxonase/arylesterase activity and oxidant-antioxidant balance in the rat.
    Bełtowski J; Wójcicka G; Mydlarczyk M; Jamroz A
    Pol J Pharmacol; 2002; 54(2):143-50. PubMed ID: 12139111
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis.
    Psaty BM; Furberg CD; Ray WA; Weiss NS
    JAMA; 2004 Dec; 292(21):2622-31. PubMed ID: 15572720
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The effect of gemfibrozil on the pharmacokinetics of rosuvastatin.
    Schneck DW; Birmingham BK; Zalikowski JA; Mitchell PD; Wang Y; Martin PD; Lasseter KC; Brown CD; Windass AS; Raza A
    Clin Pharmacol Ther; 2004 May; 75(5):455-63. PubMed ID: 15116058
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Protective effects of a squalene synthase inhibitor, lapaquistat acetate (TAK-475), on statin-induced myotoxicity in guinea pigs.
    Nishimoto T; Ishikawa E; Anayama H; Hamajyo H; Nagai H; Hirakata M; Tozawa R
    Toxicol Appl Pharmacol; 2007 Aug; 223(1):39-45. PubMed ID: 17599378
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Characteristics of a statine of the most recent generation].
    Notarbartolo A; Barbagallo CM
    Ital Heart J Suppl; 2001 Mar; 2(3):230-4. PubMed ID: 11307781
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Withdrawal of cerivastatin revealed a flaw of post-marketing surveillance system in the United States].
    Saito M; Hirata-Koizumi M; Miyake S; Hasegawa R
    Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2005; (123):41-5. PubMed ID: 16541751
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects.
    Stangier J; Rathgen K; Stähle H; Gansser D; Roth W
    Br J Clin Pharmacol; 2007 Sep; 64(3):292-303. PubMed ID: 17506785
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Steady-state pharmacokinetics of fluvastatin in healthy subjects following a new extended release fluvastatin tablet, Lescol XL.
    Barilla D; Prasad P; Hubert M; Gumbhir-Shah K
    Biopharm Drug Dispos; 2004 Mar; 25(2):51-9. PubMed ID: 14872552
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effect of food on the pharmacokinetics of rosuvastatin after administration of a single oral dose in dogs.
    Baek IH; Kwon KI; Kim MS
    Drug Res (Stuttg); 2013 Mar; 63(3):145-9. PubMed ID: 23447089
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Influence of food on pharmacokinetics of zolpidem from fast dissolving sublingual zolpidem tartrate tablets.
    Greenblatt DJ; Harmatz JS; Singh NN; Roth T; Harris SC; Kapil RP
    J Clin Pharmacol; 2013 Nov; 53(11):1194-8. PubMed ID: 23939537
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Dose proportionality and the effects of food on bioavailability of an immediate-release oxycodone hydrochloride tablet designed to discourage tampering and its relative bioavailability compared with a marketed oxycodone tablet under fed conditions: a single-dose, randomized, open-label, 5-way crossover study in healthy volunteers.
    Bass A; Stark JG; Pixton GC; Sommerville KW; Zamora CA; Leibowitz M; Rolleri R
    Clin Ther; 2012 Jul; 34(7):1601-12. PubMed ID: 22717418
    [TBL] [Abstract][Full Text] [Related]  

  • 58. HMG-CoA reductase inhibitor cerivastatin inhibits interleukin-6 expression and secretion in human adipocytes.
    van Harmelen V; Skurk T; Röhrig K; Hauner H
    Horm Metab Res; 2003 Aug; 35(8):466-70. PubMed ID: 12953163
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cerivastatin and the dissemination of adverse event information.
    Weaver SJ; Doering PL
    Ann Pharmacother; 2002 Jun; 36(6):1099-103. PubMed ID: 12058704
    [No Abstract]   [Full Text] [Related]  

  • 60. Cerivastatin approval expands HMG-CoA reductase inhibitor choices.
    Am J Health Syst Pharm; 1997 Aug; 54(16):1793. PubMed ID: 9269515
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.